Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial
Tirzepatide treatment was associated with improved self-reported HRQoL outcomes compared with placebo among people with obesity or overweight with T2D. Participants achieving greater bodyweight reductions and those with physical function limitations at baseline showed greater improvements in HRQoL. CLINICAL TRIAL REGISTRATION NUMBER FOR SURMOUNT-2: NCT04657003.
Authors
- Xiaotian Michelle Zhang (ORCID: https://orcid.org/0000-0002-4262-9128)
- Theresa Hunter (ORCID: https://orcid.org/0000-0001-8412-9175)
- Jiat Ling Poon (ORCID: https://orcid.org/0000-0001-7038-2102)
- Dachuang Cao (ORCID: https://orcid.org/0000-0003-2291-9037)
- Neena Xavier (ORCID: https://orcid.org/0000-0002-6193-3950)
- Angela Fitch (ORCID: https://orcid.org/0000-0001-9912-5994)
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1007/s13300-025-01723-w
- Citations
- 6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 7.77
Funders
- Eli Lilly and Company